Sajad Zalzala on a Human Rapamycin Trial at EARD2020

In this presentation given at Ending Age-Related Diseases 2020, Dr. Sajad Zalzala of AgelessRx discusses PEARL, a human trial of rapamycin that uses the participation of ordinary people in order to get a large sample size without the expense of a traditional clinical trial. He discusses the use and effectiveness of rapamycin as an aging treatment in previous studies of both rodents and people. He discusses the objectives of PEARL and provides reasons why this groundbreaking trial will not only provide evidence for the effectiveness of rapamycin in human beings but provide a new framework for future trials, aiding human longevity as a whole.